Payment overview · 2025
General Payments
$290.62
16 reported records · 9 companies
Healthcare provider profile · identity verified
Harbir D Singh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TUCSON, AZ · NPI 1508844846
Verified facts
What the public records show
CMS Open Payments records show Harbir D Singh, M.D. received $290.62 in general payments during 2025 across 16 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 33.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $96.98 | 33.4% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.96 | 16.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.48 | 10.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.93 | 9.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.26 | 7.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21.50 | 7.4% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $16.12 | 5.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.94 | 4.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.45 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $290.62 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $123.91 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $47.96 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.48 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| inCourage Airway Clearance Therapy Normalized: incourage airway clearance therapy |
Device | Philips North America LLC | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
57 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 462 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 329 | 48 |
| Sertraline Hcl | Sertraline Hcl | 264 | 28 |
| Divalproex Sodium | Divalproex Sodium | 251 | 41 |
| Gabapentin | Gabapentin | 250 | 32 |
| Lisinopril | Lisinopril | 243 | 40 |
| Amlodipine Besylate | Amlodipine Besylate | 239 | 53 |
| Furosemide | Furosemide | 237 | 36 |
| Trazodone Hcl | Trazodone Hcl | 233 | 33 |
| Metformin Hcl | Metformin Hcl | 228 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 219 | 29 |
| Olanzapine | Olanzapine | 182 | 17 |
| Risperidone | Risperidone | 182 | 22 |
| Potassium Chloride | Potassium Chloride | 154 | 24 |
| Mirtazapine | Mirtazapine | 133 | 21 |
| Lamotrigine | Lamotrigine | 128 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 15 |
| Losartan Potassium | Losartan Potassium | 117 | 25 |
| Simvastatin | Simvastatin | 116 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 18 |
| Eliquis | Apixaban | 98 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 95 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 16 |
| Donepezil Hcl | Donepezil Hcl | 92 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 13 |
| Lactulose | Lactulose | 77 | 13 |
| Baclofen | Baclofen | 72 | suppressed |
| Levetiracetam | Levetiracetam | 68 | suppressed |
| Carvedilol | Carvedilol | 67 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 58 | suppressed |
| Trulicity | Dulaglutide | 57 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 53 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 50 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 50 | suppressed |
| Lorazepam | Lorazepam | 48 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | suppressed |
| Clonazepam | Clonazepam | 45 | suppressed |
| Clozapine | Clozapine | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 43 | suppressed |
| Latanoprost | Latanoprost | 43 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 41 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 40 | 13 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Gemtesa | Vibegron | 35 | suppressed |
| Perseris | Risperidone | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | 12 |
| Finasteride | Finasteride | 33 | suppressed |
| Insulin Lispro | Insulin Lispro | 33 | suppressed |
| Famotidine | Famotidine | 31 | suppressed |
| Haloperidol | Haloperidol | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 27 | 15 |
| Allopurinol | Allopurinol | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 23 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Carbamazepine Er | Carbamazepine | 22 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 20 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 13 | suppressed |
| Omeprazole | Omeprazole | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Ritonavir | Ritonavir | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Darunavir | Darunavir | 11 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $290.62 · 16 records | Otsuka America Pharmaceutical, Inc. | AUSTEDO XR, Auvelity, CAPLYTA, Cologuard Collection Kit, OTEZLA, REPATHA, REXULTI, inCourage Airway Clearance Therapy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error